Parion Sciences Announces Phase I Clinical Results For Novel Dry Mouth Treatment

Parion Sciences, Inc., a privately-held, development-stage pharmaceutical company dedicated to treating diseases resulting from the failure of the body’s mucosal defenses, announced preliminary results from a Phase I clinical safety study of a novel sodium channel blocker, P-552-02, as a topical therapy for dry mouth associated with primary Sjogren’s syndrome.

More: continued here

Filed under: Endocrinology on April 8th, 2008